Alere Inc (ALR_pb.N) Key Developments | Reuters.com
Edition:
United States

Alere Inc (ALR_pb.N)

ALR_pb.N on New York Stock Exchange

336.73USD
30 Jun 2016
Change (% chg)

-- (--)
Prev Close
$336.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,451
52-wk High
$406.88
52-wk Low
$255.75

Latest Key Developments (Source: Significant Developments)

Alere HIV assay awarded WHO prequalification, making it available for public sector procurement
Thursday, 16 Jun 2016 07:00am EDT 

Alere Inc :Alere q hiv-1/2 detect assay awarded world health organization (who) prequalification , making it available for public sector procurement.  Full Article

Alere Inc - Diagnostics company Alere hit with securities fraud class action - Reuters News
Friday, 22 Apr 2016 11:18pm EDT 

Alere Inc:Diagnostics company Alere Inc has been hit with a securities fraud lawsuit accusing it of artificially inflating its share prices ahead of the Feb. 1 announcement of its proposed $5.8 billion acquisition by Abbott Laboratories Inc. - RTRS.The shareholder lawsuit, filed on Thursday in federal court in Boston, accusedAlere of misleading investors by stating that its financial reporting followed generally accepted accounting principles.The plaintiffs, a group of individual investors, citeda federal probe into the company's accounting for overseas sales in arguing that Alere had not adhered to those principle.Jackie Lustig, a spokeswoman for Alere, declined to comment on the lawsuit.  Full Article

Alere Inc Receives DOJ Subpoena Relating to U.S. Foreign Corrupt Practices Act, Unable to File 10-K - MIDTRD
Tuesday, 15 Mar 2016 09:31am EDT 

Alere Inc:Shares of Alere (ALR) were down by more than 6% in Tuesday's premarket trading after the company disclosed that on March 11, it received a subpoena from the U.S. Department of Justice - MIDTRD.relating to its sale, sales practices and dealings with third parties in Africa, Asia and Latin America, as well as other matters related to the U.S. Foreign Corrupt Practices Act.Alere is in the process of responding to the subpoena and intends to cooperated with the DOJ's investigation.Additionally, the company will be unable to file its 2015 10-K within the extension period which expired today, March 15.as it continues to conduct an analysis of certain aspects of the timing of revenue cutoff in Africa and China for the years ended December 31, 2013, 2014 and 2015, and to determine whether a material weakness existed at December 31, 2015.As a result of this delay, Alere does not expect to be able to mail a definitive proxy statement relating to its merger with Abbott Labs (ABT) until after the company files its 2015 10-K.  Full Article

Abbott Laboratories to acquire Alere for $5.8 bln
Monday, 1 Feb 2016 08:00am EST 

Abbott Laboratories:To acquire Alere, becoming leader in point of care testing and significantly advancing global diagnostics presence.Abbott will pay $56 per common share at a total expected equity value of $5.8 billion.Says transaction expected to be immediately accretive to abbott's ongoing earnings per share upon close.Combination is anticipated to result in annual pre-tax synergies approaching $500 million by 2019.Sees approximately 12-13 cents of accretion in 2017 and more than 20 cents in 2018 from deal.Under the terms of the agreement, Alere will become a subsidiary of Abbott.Transaction has been approved by the boards of directors of Alere and Abbott.Evercore is acting as financial advisor and Kirkland & ellis llp is serving as legal counsel to Abbott.JP Morgan is acting as financial advisor and cravath, swaine & Moore is serving as legal counsel to Alere.  Full Article

Alere Inc completes divestiture of BBI Group
Thursday, 19 Nov 2015 07:00am EST 

Alere Inc:Completes divestiture of BBI Group.Total purchase price was $115 million.Alere is eligible to receive up to an additional $47 million in contingent consideration.Intends to use all of the proceeds to pay down existing indebtedness.  Full Article

Alere Inc receives U.S. HHS approval to electronically process Drug Tests for department of transportation regulated employees
Thursday, 15 Oct 2015 07:00am EDT 

Alere Inc:Receives U.S. HHS approval to electronically process Drug Tests for department of transportation regulated employees.  Full Article

Alere Inc declares cash dividend
Tuesday, 1 Sep 2015 07:00am EDT 

Alere Inc:Says it has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock.Says the dividend is payable on Oct. 15 to holders of record of Series B stock at the close of business on Oct. 1.  Full Article

Alere Inc reaffirms FY 2015 guidance
Tuesday, 4 Aug 2015 07:00am EDT 

Alere Inc:Expects FY 2015 net revenue to be in the range of $2.5 billion to $2.6 billion.Expects FY 2015 non-GAAP adjusted net income from continuing operations available to common stockholders in the range of $2.40 to $2.50 per diluted share.FY 2015 revenue of $2.56 billion and EPS of $2.43 - Thomson Reuters I/B/E/S.  Full Article

Alere Inc receives FDA CLIA waiver for Alere i Strep A Rapid Molecular Test
Thursday, 16 Jul 2015 07:00am EDT 

Alere Inc:Says U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere i Strep A test.  Full Article

Alere to sell BBI Group and acquisition of US diagnostics
Thursday, 16 Jul 2015 07:00am EDT 

Alere Inc:Continues to execute on core business strategy through agreement to sell bbi group and acquisition of US diagnostics.Says expects the two transactions combined to be dilutive to earnings per share by approximately $0.00-$0.05 in 2015.Says Alere has acquired substantially all of the assets of US diagnostics (usd) for $60 million in cash.On July 2, 2015, Alere signed agreement to sell its bbi business to exponent private equity llp, for about $164 million.  Full Article

BRIEF-Alere HIV assay awarded WHO prequalification, making it available for public sector procurement

* Alere q hiv-1/2 detect assay awarded world health organization (who) prequalification , making it available for public sector procurement Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)